Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
17 March 2021 - 10:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
March 17, 2021
Commission File Number: 001-39363
IMMATICS N.V.
Paul-Ehrlich-Straße 15
72076 Tübingen, Federal Republic
of Germany
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will
file annual reports under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT
ON FORM 6-K
On March 17, 2021, Immatics N.V. (the “Company”)
issued a press release providing a data update on dose escalation from its ongoing ACTengine® cell therapy programs.
A copy the press release is attached hereto as Exhibit 99.1.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
IMMATICS
N.V.
|
|
|
|
|
Date: March 17, 2021
|
by:
|
|
/s/
Harpreet Singh
|
|
|
|
|
Harpreet Singh
|
|
|
|
|
Chief Executive Officer
|
|
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Apr 2024 to May 2024
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From May 2023 to May 2024